tp-3654
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 16, 2019 (NCT03715504)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase PIM1INHIBITOR
PIM1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)[C@H]1CC[C@H](Nc2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3n2)CC1- Mol. weight
- 418.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3975308 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06389955 | Phase 1 | May 22, 2023 | Sumitomo Dainippon |
| NCT04176198 | Phase 1 | Dec 31, 2019 | Boston Biomedical |
| NCT03715504 | Phase 1 | Apr 16, 2019 | Tolero Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Biomedical | For profit | 1 | 1 | 1 | 2019 |
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2023 |
| Tolero Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1